For example, the use of probiotic treatments with Lactobacillus casei strain Shirota over 8 weeks significantly reduced inflammatory markers in ME/CFS patients [89]; whereas, an oral intake of Bifidobacterium infantis 35624 for 8 weeks decreased concentrations of pro-inflammatory markers, including CRP and IL-6, compared with the baseline in 70% of ME/CFS patients, thereby suggesting that B. infantis 35,624 benefits are not limited to mucosal responses and they can exert an effect systemically [99]. The gene discussed is IL6; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.